BioArctic

BioArctic Current Assets

The Current Assets of BioArctic (BIOA B.ST) as of Sep 27, 2026 is 2.20 B SEK. In the previous year, Current Assets was 903.93 M SEK — a change of 143.39% (higher).

Current Assets

2.20 BSEK

YoY

143.39%

Last updated:

Current Assets of BioArctic is 2026 2.20 B SEK. Current Assets of BioArctic was 2025 903.93 M SEK. It decreases by 143.39% higher compared to the previous year.

The BioArctic Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
919.75 M SEK
Jan 1, 2019
1.14 B SEK
Jan 1, 2020
1.01 B SEK
Jan 1, 2021
867.99 M SEK
Jan 1, 2022
828.80 M SEK
Jan 1, 2023
1.16 B SEK
Jan 1, 2024
903.93 M SEK
Jan 1, 2025
2.20 B SEK
The BioArctic Current Assets history
YEARCurrent AssetsYoY
2.20 BSEK+143.39%
903.93 MSEK-22.05%
1.16 BSEK+39.92%
828.80 MSEK-4.52%
867.99 MSEK-14.16%
1.01 BSEK-11.09%
1.14 BSEK+23.66%
919.75 MSEK-18.84%
1.13 BSEK+61.76%
700.62 MSEK+494.76%
117.80 MSEK—
Access this data via the Eulerpool API
Get Free API Key

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Current Assets of BioArctic is 2.20 B SEK in 2026.

Current Assets of BioArctic changed from 903.93 M SEK to 2.20 B SEK, representing a 143.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Assets BioArctic since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's BioArctic historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — BioArctic

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — BioArctic